

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

Application Number	10/757,623
Filing Date	11/14/08
First Named Inventor	M. Bogenstaetter et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1614

[illegible]

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		EP	0 978 512	A1	Societe Civile Bioprojet	02-09-2000		
		WO	99/42458		James Black Foundation Limited	08-26-1999		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3.

Application Number	10/257,625
Filing Date	1/14/04
First Named Inventor	M. Bogenstaetter et al.
Group Art Unit	1624
Examiner Name	McKenzie
Attorney Docket Number	ORT-1614

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		ARRANG, J.M. et al.; "Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor" Nature; April 1983; 302:832-837	
		ASH, A.S.F. et al; "Receptors Mediating Some Actions of Histamine"; Br. J. Pharmac. Chemother.; 1986 27:427-439	
		BARNES, J.C. et al; "The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo"; Soc. Neurosci. Abstr.; 1993 19:1813	
		Bloworld Today, March 2, 1999, page 3	
		BLACK, J.W. et al.; "Definition and Antagonism of Histamine H2-receptors"; Nature; April 1972; 236:385-390	
		DING, Y. S. et al. "Synthesis of High Specific Activity (+)-and(-)-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction". J. Med. Chem. (1991) 34:767-771	
		GANELLIN, C.R. et al.; "Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists"; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1998 331:395-404	
		GARBAG, M. et al; "S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist"; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310	
		GILATECH, INC.; "Gilatech's first drug candidate begins phase I human clinical trials"; Gilatech Inc. Press Release; November 5, 1998	
		ICHINOSE, M. et al; "Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo"; P.J. Eur. J. Pharmacol; 1989; 174:49-55	
		IMAMURA, M. et al.; "Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2"; J. Pharmacol. Exp. Ther.; 1994; 271(3):1259-1266	
		JONES, R.G. "Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboxylates from Glycine and Substituted Glycine Esters" J Am. Chem Soc. (1949) 71:844-847	
		KORTE, A. et al; "Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine"; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-988	
		KRAUSE, M. et al.; "The Histamine H3 Receptor-A Target for New Drugs"; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-196	
		LEURS, R. et al; "The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor" Prog. Drug. Res.; 1995; 45:107-165	
		LIN, Jian-Sheng et al. "Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat"; Brain Res.; 1990; 523:325-330	
		LINNEY, I.D. et al; "Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists"; J. Med. Chem.; 2000; 43:2362-2370	
		LOVENBERG, T.W. et al; "Cloning and Functional Expression of the Human Histamine H3 Receptor"; Mol. Pharmacol; 1999 55:1101-1107	
		LOVENBERG, T.W. et al. "Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293:771-778	
		MACHIDORI, H. et al; "Zucker obese rats: defect in brain histamine control of feeding"; Brain Res.; 1992; 590:180-186	
		MCLEOD, R.L. et al; "Antimigraine and Sedative Activity of SCH 50871: A Novel Orally-Active Histamine H3 Receptor Agonist"; Soc. Neurosci. Abstr.; 1998; 22:2010	
		MONTI, J.M. et al; "Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness"; Eur. J. Pharmacol.; 1991; 205:283-287.	
		MORISSET, S. et al; "High constitutive activity of native H3 receptors regulates histamine neurons in brain"; Nature; Dec., 2000; 408:860-864	
		ODA, Tamaki et al.; "Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes"; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786	
		PANULA, P. et al.; "Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease" Soc. Neurosci. Abstr.; 1995; 21:1977	
		PHELPS, M.E. "Positron Emission Tomography Provides Molecular Imaging of Biological Processes." Proc. Natl. Acad. Sci. (2000) 97:9226-9233	
		PHILLIPS, J.G.; ALI, S.M. "In the Histamine H3 Receptor-A Target for New Drugs" Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Application Number	10/353,625	
Filing Date	11/14/04	
First Named Inventor	M. Bogenstaetter et al.	
Group Art Unit	1629	
Examiner Name	McKoy	
Attorney Docket Number	ORT-1614	

[illegible]

Examiner Signature	<i>Thomas M. El...</i>	Date Considered	3/7/06
--------------------	------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Approved for use through 10/31/2002. OMB 0651-0031.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

10757 625

11104

M. Bogenstaetter et al.

1024

1974

ORT-1614

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date _____

2019	Considered
------	------------

3/7/06

Signature	<i>[Signature]</i>	Concurrence	<i>[Signature]</i>
-----------	--------------------	-------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Thomas McElroy

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/737/21
Filing Date	1/17/01
First Named Inventor	M. Bogenstaetter et al.
Group Art Unit	1824
Examiner Name	
Attorney Docket Number	ORT-1614

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	3/7/06
-----------------------	--------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2.

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

9757, 623

M. Bogenstaetter et al.

1628

McRae
ORT-1614

ORT-1614

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

3/7/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Washington, DC 20231.